|
Getting your Trinity Audio player ready...
|
Seoul, South Korea – July 29, 2025
South Korean biopharmaceutical company Celltrion announced Tuesday that it has been selected as the preferred bidder to acquire a U.S.-based pharmaceutical manufacturing facility from an undisclosed global firm. The move is part of Celltrion’s strategy to mitigate potential risks associated with proposed U.S. tariffs on pharmaceutical imports.
Founder and CEO Seo Jung-jin stated during a press briefing that the company plans to invest approximately 700 billion won (USD $503.78 million) in the acquisition and operation of the facility. Additional investment of between 300 billion and 700 billion won may follow, contingent on future U.S. tariff policy developments.
The announcement comes amid a national security investigation by the U.S. government into the pharmaceutical sector. Earlier this month, President Donald Trump indicated that tariffs on pharmaceutical products could reach up to 200%, suggesting such measures could raise drug prices, reduce foreign competition, and improve domestic profitability.
Celltrion declined to disclose further details, including the seller’s identity and the facility’s location, citing confidentiality until the final agreement is signed, which is expected by early October.
